Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Conditions
Keywords
MDS, AML, Azacitidine, Lenalidomide, del5q
Brief summary
The proposed phase II trial is a multicenter, randomized, open-label study that will evaluate the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) with a karyotype including del(5q). The primary objective will be to evaluate the efficacy in terms of response according to International Working Group (IWG) criteria for MDS and AML after 6 cycles of azacitidine or azacitidine + lenalidomide treatment, or at end of study if this occurs at an earlier time point.
Detailed description
This is an prospective open multi-center randomized phase II study of standard dose azacytidine with or without the addition of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q). Seventy-two patients, eligible for treatment with azacytidine (Intermedium/INT-2 and High-risk MDS and AML with 20-30 % marrow blasts according to label) will be included. Azacytidine will be given in a modified standard dose, azacytidine 5+2 (75 mg/m2/ d subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacytidine 75 mg/m2/ d for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles. Cycle interval may be prolonged if toxicity according to predefined criteria occurs. Patients will be randomized to azacytidine (Arm A) or azacytidine + lenalidomide (Arm B). The initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacytidine cycle and leaving the last week before start of next azacytidine cycle free. The dose should be increased to 20 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. The total study period is 24 weeks + additional weeks caused by prolonged cycle interval. Patients, who following a response may be eligible for allo-SCT may exit the study after cycle 3, 4 or 5 and then be subject to end-of-study assessment. Patients who at start of treatment, or any time during study have a neutrophil count \<0,5 x 109/l will be treated with Granulocyte-ColonyStimulatingFactor (G-CSF).
Interventions
DRUGAzacitidine
Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
DRUGazacitidine + lenalidomide
Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles. Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks.
Sponsors
Nordic MDS Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age at the time of signing the informed consent form. * MDS with IPSS Int-2 or High with a karyotype including del(5q). * Acute myeloid leukaemia (AML) with multilineage dysplasia and 20-30 % blasts (former RAEB-t) with a karyotype including del(5q). * Subject has signed the informed consent form. * Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test prior to starting lenalidomide. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, patches, or implantable hormonal contraceptive methods; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on lenalidomide. WCBP must agree to have pregnancy tests every 4 weeks while on lenalidomide. * Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on lenalidomide, when temporarily stopping lenalidomide and 28 days after the last dose of lenalidomide. Note: Refractory and relapsed patients can be included as long as they fulfil the inclusion criteria.
Exclusion criteria
* Eligible for upfront allogeneic SCT without prior induction chemotherapy or azacitidine * Pregnant or lactating females. * Prior therapy with azacitidine * Prior therapy with lenalidomide * Expected survival less than two months. * Acute promyelocytic leukemia (APL) * Central nervous system leukemia * Serum biochemical values as follows 1. Serum creatinine \>2.0 mg/dL (177 mmol/L) 2. Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transferase (ALT)/serum glutamate pyruvate transaminase (SGPT) \>3.0 x upper limit of normal (ULN) 3. Serum total bilirubin \>1.5 mg/dL * Prior allergic reaction to thalidomide * Uncontrolled systemic infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response according to IWG criteria for MDS and AML | 25-44 weeks (after 6 cycles of azacitidine or azacitidine+lenalidomide) | Response according to IWG criteria include hematologic response (including transfusion independence), bone marrow response (blast count) and cytogenetic response (karyotype) after 6 cycles of azacytidine or azacytidine+lenalidomide. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 44 weeks the maximum Time Frame. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety (number and types of adverse advents) in azacitidine vs azacitidine + lenalidomide groups | 25-44 weeks | Heamtological adverse events will be monitored by checking Hemoglobin,Leucocyte count, Platelet and a Differential every week. Non-Hematological adverse events will be monitored and reported in the Case report form (CRF). For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 44 weeks the maximum Time Frame. |
| Azacitidine cycle interval between groups | 25-44 weeks | For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 44 weeks the maximum Time Frame. |
| Cytogenetic response after 3 cycles using Fluorescence In Situ Hybridization(FISH) | 25-44 weeks | After 3 cycles the 5q- clone will be measured with FISH to see if there is a response already at that time. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 44 weeks the maximum Time Frame. |
| Relapse in azacitidine vs azacitidine + lenalidomide groups | Up to week 156 | All patients will undergo follow-up once yearly from start of treatment; week 52, 104, and 156. |
| Analysis of a broad spectrum of molecular and cellular events which previously have been identified as related to MDS with del(5q). | 25-44 weeks | Bone marrow will be biobanked at inclusion and after 6 cycles of treatment or or at end of study if this occurs at an earlier time point. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 44 weeks the maximum Time Frame. |
| Survival in azacitidine vs azacitidine + lenalidomide groups | Up to week 156 | All patients will undergo follow-up once yearly from start of treatment; week 52, 104, and 156. |
Countries
Sweden
Contacts
Primary ContactLars Möllgård, MD, PhD
Backup ContactBengt Rasmussen, MD
Outcome results
None listed